Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Finerenone versus eplerenone in Japanese patients hospitalized for worsening chronic heart failure
jRCT2080222262Phase 2Completed
- Sponsor
- Bayer
- Start
- Oct 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of finerenone in chronic heart failure (CHF), heart failure with reduced ejection fraction (HFrEF), type 2 diabetes mellitus (T2DM) and 1 more (6 arms), sponsored by Bayer. Primary endpoint: NT-proBNP responder rate at Day 90. Started Oct 2013; status: completed.
02
Drugs
finerenone
03
Conditions
chronic heart failure (CHF)heart failure with reduced ejection fraction (HFrEF)type 2 diabetes mellitus (T2DM)chronic kidney disease (CKD)
Beyond the preview
Go deeper on jRCT2080222262.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222262.